Sanofi to Evaluate THOR-707 with Merck's Checkpoint Inhibitor Keytruda

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Oct 29, 2020 at 12:32 PM.

  1. #1 cafead, Oct 29, 2020 at 12:32 PM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    33,046
    Likes Received:
    3
    via Sanofi is partnering with Merck to test its THOR-707 compound with Merck’s checkpoint inhibitor Keytruda (pembrolizumab) in solid tumors. THOR-707 is a non-alpha IL-2 candidate that is currently being studied in Phase I trials in solid tumors.

    article source
     
    Quote

Reply to Thread